U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results in this book: 16

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Sep.

Table of contents

1.

Results.

2.

Appendix 6, Summary of Study 003 and Study 005.

3.

Executive Summary.

4.

Appendix 1, Patient Input Summary.

5.

Appendix 5, Validity of Outcome Measures.

6.

Appendix 2, Literature Search Strategy.

7.

Introduction.

8.

Objectives and Methods.

9.

Submission History.

10.

Appendix 4, Detailed Outcome Data.

11.

Discussion.

12.

Appendix 3, Excluded Studies.

13.

Clinical Review Report: Levodopa/Carbidopa (Duodopa): (Abbvie Corporation): Indication: For the treatment of patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products, and, for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube required for administration [Internet].

14.

References.

15.

Conclusions.

16.

Abbreviations.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On
  • 84604-20-6 OR SODIUM SULFATE ANHYDROUS OR PTELEA TRIFOLIATA BARK ... (16233)
    84604-20-6 OR SODIUM SULFATE ANHYDROUS OR PTELEA TRIFOLIATA BARK OR VERBENA OFFICINALIS FLOWERING TOP OR RADISH OR MAGNESIUM CATION OR CICHORIUM INTYBUS FLOWER OR SCHISANDRA CHINENSIS FRUIT OR NEOPICRORHIZA SCROPHULARIIFLORA ROOT OR VISCUM ALBUM FRUITING TOP OR LACTIC ACID, L- OR PHENOL OR BERBERIS VULGARIS ROOT BARK OR SULFUR IODIDE OR CHROMIC CATION OR CUPRIC CATION OR CHELIDONIUM MAJUS OR TARAXACUM OFFICINALE OR COBALTOUS CATION OR SUS SCROFA GALLBLADDER OR PORK LIVER OR STRYCHNOS NUX-VOMICA SEED OR VANADIUM[all]
    Search
    Books

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...